Related Experiment Videos
Immunotherapy of human papillomavirus-associated malignancies and the challenges posed by T-cell tolerance
1Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
Human papillomaviruses are associated with a broad range of carcinomas, including cervical cancer. Although the delivery of immunogenic tumor-associated antigens represents a promising approach in the treatment of these malignancies, the imposition of T cell tolerance poses a significant challenge in this endeavor. The purpose of this review is to discuss T cell tolerance and the role of T cell costimulation in the immunotherapy of HPV-associated malignancies.
Insights
Human papillomaviruses (HPV) drive many cancers. Overcoming T cell tolerance is key for effective immunotherapy against HPV-associated malignancies, with T cell costimulation showing promise.
Area of Science:
- Oncology
- Immunology
- Virology
Background:
- Human papillomaviruses (HPV) are oncogenic viruses linked to various carcinomas, notably cervical cancer.
- Immunotherapy using tumor-associated antigens is a promising strategy for treating these HPV-driven cancers.
- A major hurdle in this approach is the development of T cell tolerance, which suppresses anti-tumor immune responses.
Purpose of the Study:
- This review discusses the mechanisms of T cell tolerance in the context of HPV-associated malignancies.
- It explores the critical role of T cell costimulation in overcoming this tolerance.
- The aim is to highlight strategies for enhancing immunotherapy efficacy against these cancers.
Main Methods:
- This is a review article, synthesizing existing research.
- It analyzes the immunological principles of T cell tolerance.
- It examines the function and therapeutic potential of T cell costimulatory signals.
Main Results:
- T cell tolerance can significantly impede the effectiveness of cancer immunotherapy.
- T cell costimulation is essential for robust T cell activation and sustained anti-tumor immunity.
- Targeting costimulatory pathways offers a viable strategy to enhance immunotherapeutic outcomes.
Conclusions:
- Effective immunotherapy for HPV-associated malignancies requires overcoming T cell tolerance.
- Enhancing T cell costimulation is a crucial therapeutic avenue.
- Further research into costimulatory molecules may lead to improved cancer treatments.